October: Breast Cancer Awareness Month | Fertility Preservation After Diagnosis

October is Breast Cancer Awareness Month, a time to focus not only on early detection and treatment, but also on an aspect of care that is often overlooked: fertility preservation.

Breast cancer is the most common cancer in women of reproductive age. More young women are surviving than ever, but chemotherapy, radiation, and endocrine therapy can damage the ovaries. The good news is that fertility preservation is now a standard part of comprehensive breast cancer care.

This article explains how treatment affects fertility, what options exist, and how to balance cancer care with future family goals.

How Breast Cancer Treatment Affects Fertility

1. Chemotherapy is the biggest threat to ovarian function. Alkylating agents like cyclophosphamide are the most toxic and can cause early menopause. Radiation to the pelvic area can also damage the ovaries.

2. Endocrine therapy for hormone-positive breast cancer usually lasts 5-10 years, during which pregnancy is not advised, narrowing the childbearing window.

3. The impact varies by age, regimen, and ovarian reserve. Younger patients are more likely to recover ovarian function, but individual differences are large. A reproductive specialist can assess your situation.

The Time Window: The Key to Balancing Both

The core tension in fertility preservation is time. Cancer treatment often needs to begin quickly, while fertility preservation takes time.

In 2026, the American Society for Reproductive Medicine (ASRM) updated its committee opinion on fertility preservation, clearly stating that patients preparing to undergo gonadotoxic chemotherapy or pelvic radiation therapy should receive prompt counseling about their fertility preservation options.

ASRM 2026 guidelines emphasize a same-day referral so patients can discuss options before starting chemotherapy or radiation. If treatment must begin within two weeks, random-start ovarian stimulation can be used, no need to wait for your next period.

Counseling doesn’t mean you must proceed. Even if you’re unsure, a reproductive specialist can help you understand your choices.

Fertility Preservation Options for Women with Breast Cancer

1. Egg and Embryo Cryopreservation

Egg and embryo freezing are the first-line options according to ASRM and ASCO guidelines.

Ovarian stimulation for egg retrieval typically takes about two weeks. For patients who need to start chemotherapy urgently, random-start protocols allow stimulation to begin immediately, without waiting for the next menstrual cycle.

2. Special Considerations: The Letrozole Protocol

Many patients worry that the estrogen rise during stimulation could fuel tumor growth. The evidence is reassuring. 

A 2026 review in Current Breast Cancer Reports confirmed that letrozole and anastrozole are widely used and safe for breast cancer patients.

The POSITIVE trial also found that temporarily interrupting endocrine therapy to try for pregnancy does not increase breast cancer recurrence risk. In that trial, 76% of women achieved pregnancy and 69% had a live birth.

3. Ovarian Tissue Cryopreservation: When Treatment Cannot Be Delayed

For patients who cannot delay chemotherapy or who have contraindications to hormonal stimulation, ovarian tissue cryopreservation is an important alternative. ASRM classifies it as an established strategy.

A meta-analysis including 459 women reported that after orthotopic transplantation (grafting tissue back into pelvic anatomy), 34% achieved at least one live birth. 

The main risk to be aware of is reintroduction of malignant cells, which occurs in approximately 1% of cases, with the highest risk in leukemia patients. Pathological examination of the tissue before transplantation is essential; tissue containing malignant cells is typically not used.

4. GnRH Agonists: An Adjunct, Not a Replacement

ASRM guidelines clearly state that GnRH agonists should not be used in place of established fertility preservation methods, but may be offered as an adjunct for breast cancer patients.

ASCO notes that they may improve the chance of preserving ovarian function and pregnancy during chemotherapy.

Fertility Preservation for Male Cancer Patients

Male breast cancer is rare, but fertility preservation is equally important for men facing cancer treatment.

Sperm cryopreservation is the standard fertility preservation method recommended by both ASCO and ASRM. If a semen sample cannot be provided, testicular sperm extraction may be possible.

An important caveat: Sperm collected soon after cancer-directed therapy initiation and completion may carry higher genetic damage risks, making pre-treatment samples the most ideal.

For prepubertal boys, testicular tissue cryopreservation remains experimental and should only be offered in a clinical trial.

Special Considerations for Children and Adolescents

For prepubertal girls, ovarian tissue cryopreservation is the only established fertility preservation method. This technique can be performed immediately without delaying cancer treatment.

For prepubertal boys, testicular tissue cryopreservation is still experimental. ASRM guidelines also advise against creating embryos for minor patients, to preserve their future family-building options.

Multidisciplinary Collaboration and Decision Support

ASRM 2026 guidelines emphasize that preservation works best with a team including oncologists, reproductive specialists, mental health professionals, and financial navigators.

1. Oncology teams should discuss fertility risks at diagnosis and initiate prompt referral.

2. Reproductive specialists provide rapid assessment and individualized preservation plans.

3. Psychological support should be integrated into the counseling process. Psychological support helps patients feel confident in their decisions.

4. Financial navigation is recognized as a core clinical pillar. ASRM now recognizes dedicated financial navigators as essential to help patients understand their options quickly and clearly.

The Bottom Line

According to 2026 clinical guidelines, patients should discuss fertility preservation with their oncology team before starting treatment.

Safe preservation approaches exist for breast cancer patients. Multidisciplinary care allows patients to preserve fertility without delaying cancer treatment.

If you have been diagnosed with breast cancer and hope to have children later, raise fertility concerns with your care team early; fertility preservation should be considered from the start of treatment planning.

For more information about fertility preservation for cancer patients, email info@cefivf.com or visit our Contact page.

Disclaimer: This article is based on the ASRM 2026 committee opinion, and peer-reviewed research published in 2025-2026. It is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for personalized guidance.